Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649360 | 0.88 | SIGMAR1 (0.48) | SIGMAR1MCHR1ALDH1A1NPSR1DRD2 | |
| SCHEMBL4925914 | 0.86 | HDAC8 (0.48) | PTPN1HDAC8NPSR1 | |
| SCHEMBL4648949 | 0.85 | PTPN1 (0.45) | PTPN1HDAC8ALDH1A1DRD2TSHR | |
| SCHEMBL4649247 | 0.83 | SIGMAR1 (0.44) | SIGMAR1MCHR1ALDH1A1NPSR1DRD2 | |
| SCHEMBL4925770 | 0.82 | PTPN1 (0.44) | PTPN1HDAC8DRD2 | |
| SCHEMBL3562002 | 0.81 | PTPN1 (0.58) | PTPN1HDAC8ALDH1A1TSHRLMNA | |
| SCHEMBL4914651 | 0.78 | HDAC8 (0.50) | PTPN1HDAC8NPSR1 | |
| SCHEMBL4649677 | 0.77 | SIGMAR1 (0.46) | SIGMAR1MCHR1ALDH1A1NPSR1DRD2 | |
| SCHEMBL4649730 | 0.76 | NAMPT (0.42) | SIGMAR1ALDH1A1TSHR | |
| SCHEMBL4822180 | 0.75 | PTPN1 (0.46) | PTPN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| EP-1904495-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007281-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | PTPN1 1948/4885SIGMAR1 366/4885MCHR1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.